Keyphrases
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
100%
Outcome Prediction
100%
Clinical Predictors
100%
Immune Checkpoint Inhibitors
100%
Overall Survival
100%
Real-world Outcomes
100%
Immune Checkpoint Inhibitor Monotherapy
100%
Eastern Cooperative Oncology Group Performance Status (ECOG PS)
100%
Non-small Cell Lung Cancer (NSCLC)
66%
Small Cell Lung Cancer
66%
Confidence Interval
66%
Predictive Factors
66%
Body Mass Index
66%
Median Overall Survival
66%
Median Progression-free Survival
66%
Survival Outcomes
66%
Subsequent Line
66%
Immune-related Adverse Events
66%
Pre-existing Autoimmune Disease
66%
Patient Demographics
33%
Medical Records
33%
Real-world Population
33%
Old Age
33%
First-line Therapy
33%
Treatment Outcome
33%
Clinical Benefit
33%
Disease Flare
33%
Objective Response Rate
33%
Hazard Ratio
33%
Cox Regression Model
33%
Progression-free Survival
33%
Non-small Cell Lung Cancer Cells
33%
Poor Performance Status
33%
Treatment Paradigms
33%
Real Patients
33%
IrAE
33%
Performance Status Score
33%
Medicine and Dentistry
Lung Cancer
100%
Monotherapy
100%
Predictor
100%
Immune Checkpoint Inhibitor
100%
Overall Survival
100%
Oncology
60%
Non Small Cell Lung Cancer
60%
Progression Free Survival
60%
Small Cell Lung Cancer
40%
Body Mass Index
40%
Predictive Factor
40%
Autoimmune Disease
40%
Immune-Related Adverse Events
40%
Disease Exacerbation
20%
Patient Population
20%
Medical Record
20%
Proportional Hazards Model
20%
Hazard Ratio
20%
Pharmacology, Toxicology and Pharmaceutical Science
Immune Checkpoint Inhibitor
100%
Lung Cancer
100%
Overall Survival
100%
Monotherapy
100%
Non Small Cell Lung Cancer
60%
Progression Free Survival
60%
Small Cell Lung Cancer
40%
Adverse Event
40%
Autoimmune Disease
40%
Disease Exacerbation
20%
Immunology and Microbiology
Overall Survival
100%
Progression Free Survival
60%
Autoimmune Disease
40%
Body Mass
40%
Medical Record
20%